Urology

Researchers reported that lidocaine did not affect POUR rates but enhanced early recovery metrics after SUI surgery.

Review some of the top stories from the Contemporary OB/GYN website over the past week and catch up on anything you may have missed.

GSK, Spero Therapeutics, resubmitted an NDA for tebipenem HBr, an oral carbapenem antibiotic, for treating complicated UTIs, supported by phase 3 trial data.

The updated Revi System streamlines management of urgency urinary incontinence, with an easy-to-use design and a strong body of clinical evidence.

The FDA has approved injectable fosfomycin for adults with complicated urinary tract infections, offering a new treatment option against multidrug-resistant bacteria.

A new study reveals that nearly 20% of urinary tract infections in Southern California may stem from E. coli strains found in contaminated meat.

Tebipenem HBr met primary endpoints in a phase 3 trial, showing oral efficacy comparable to IV carbapenem for complicated urinary tract infections.

The 2025 amendment updates diagnostic, treatment, and prevention strategies for recurrent urinary tract infections in women.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Oral sulopenem (ORLYNVAH; Iterum Therapeutics) was non-inferior to amoxicillin/clavulanate for treating uUTIs in women, per the phase 3 REASSURE trial.

A new randomized trial shows Er:YAG laser therapy offers no significant benefit over sham treatment for managing female stress urinary incontinence at 6 months.

GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial for tebipenem HBr, a potential first oral carbapenem for cUTIs in the United States, was stopped early because of positive efficacy results.

In this Q&A, Karyn S. Eilber, MD, shares some of the biggest takeaways from the new AUA/SUFU/AUGS 2025 Guidelines on Genitourinary Syndrome of Menopause.

A new study finds no significant difference in symptom improvement between onabotulinumtoxinA injections and midurethral sling surgery for women with mixed urinary incontinence.

A new study reveals that virtual pelvic floor therapy is just as effective as in-person treatment for postpartum women with stress urinary incontinence.

New guidelines on GSM recommends symptom-based diagnosis, shared decision-making, and local estrogen as first-line therapy to improve quality of life.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

New research reveals a significant link between urinary incontinence and increased cardiovascular disease risk, even without reduced physical activity.

The approval marks a vital step toward care for urinary tract infections, helping to reduce recurrence and improve patients’ quality of life.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Many women struggle with stress urinary incontinence but delay treatment because of embarrassment and lack of awareness, highlighting a need for screening and innovative treatments.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

John PFA Heesakkers, MD, PhD, MBA, with Maastricht Universitair Medisch Centrum, highlights a study revealing that the Revi System significantly reduces urinary incontinence episodes, offering a side-effect-free alternative to traditional treatments with high patient satisfaction.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Jannah Thompson, MD, FPMRS, discusses how the Neuspera sacral neuromodulation system encourages patient involvement, improving long-term treatment success and offering broader applicability for those with urge urinary incontinence.